Match!
Tareq Al Baghdadi
Mercy Medical Center (Baltimore, Maryland)
PathologyOncologyPalbociclibPancreatic cancerMedicine
7Publications
2H-index
61Citations
What is this?
Publications 6
Newest
#1Sandip Pravin Patel (UCSD: University of California, San Diego)H-Index: 16
#2Megan Othus (Fred Hutchinson Cancer Research Center)H-Index: 31
Last. Tareq Al Baghdadi (Mercy Medical Center (Baltimore, Maryland))H-Index: 2
view all 22 authors...
Purpose: Immune checkpoint blockade has improved outcomes across tumor types; little is known about the efficacy of these agents in rare tumors. We report the results of the (non-pancreatic) neuroendocrine neoplasm cohort of SWOG S1609 Dual Anti-CTLA-4 & Anti-PD-1 blockade in Rare Tumors (DART). Experimental Design: We performed a prospective, open-label, multicenter phase 2 clinical trial of ipilimumab plus nivolumab across multiple rare tumor cohorts, with the (non-pancreatic) neuroendocrine c...
1 CitationsSource
#1Tareq Al BaghdadiH-Index: 2
#2Susan Halabi (Duke University)H-Index: 60
Last. Richard L. Schilsky (American Society of Clinical Oncology)H-Index: 66
view all 14 authors...
PURPOSEThe Targeted Agent and Profiling Utilization Registry (TAPUR) Study identifies signals of antitumor activity of commercially available targeted agents in patients with advanced cancers that ...
Source
#2Mary W. RedmanH-Index: 25
Last. David R. GandaraH-Index: 76
view all 17 authors...
9022Background: This signal finding study was designed to evaluate the clinical efficacy of a PARP inhibitor, talazoparib, in advanced stage squamous cell lung cancer harboring HRRD. Methods: Eligi...
#1Tareq Al BaghdadiH-Index: 2
#2Susan Halabi (Duke University)H-Index: 60
Last. Richard L. Schilsky (American Society of Clinical Oncology)H-Index: 66
view all 15 authors...
2532Background: The TAPUR Study is a phase II multi‐basket study that evaluates the anti‐tumor activity of commercially available targeted agents in pts with advanced cancers with genomic alteratio...
21 CitationsSource
#1Vincent Chung (City of Hope National Medical Center)H-Index: 15
#2Shannon McDonough (Fred Hutchinson Cancer Research Center)H-Index: 10
Last. Howard S. Hochster (Yale Cancer Center)H-Index: 43
view all 16 authors...
Importance KRAS mutations are common in pancreatic cancer, but directly targeting the KRAS protein has thus far been unsuccessful. The aim of this trial was to block the MEK and PI3K/AKT pathways downstream of the KRAS protein as an alternate treatment strategy to slow cancer growth and prolong survival. This was the first cooperative group trial to evaluate this strategy using molecularly targeted oral combination therapy for the treatment of chemotherapy-refractory pancreatic cancer. Objective...
38 CitationsSource
#1Philip A. PhilipH-Index: 54
#2Jill LacyH-Index: 18
Last. Pascal HammelH-Index: 59
view all 20 authors...
TPS477 Background: In pts with LAPC, more effective systemic therapies may be associated with improved local control, delay of metastasis, and overall survival (OS). The phase III MPACT trial in pts with metastatic PC demonstrated longer OS (median, 8.7 vs 6.6 mos; HR, 0.72; P 1, or clinically significant ascites are ineligible. Pts will receive nab-P 125 mg/m2 + Gem 1000 mg/m2 on days 1, 8, and 15 of each 28-day cycl...
2 CitationsSource
1